期刊文献+

首荟通便胶囊治疗2型糖尿病患者口服阿卡波糖后腹胀的有效性及安全性

Efficacy and Safety of Shouhui Tongbian Capsule in the Treatment of Abdominal Distension in Type 2 Diabetes Patients after Oral Acarbose
原文传递
导出
摘要 目的探讨首荟通便胶囊治疗2型糖尿病患者口服阿卡波糖后腹胀的有效性及安全性。方法选取2021年1—12月沧州市中心医院收治的48例口服阿卡波糖后腹胀的2型糖尿病患者作为研究对象,按随机数字表法分为对照组与观察组,各24例。对照组给予生活干预,观察组在对照组基础上口服首荟通便胶囊,比较两组的治疗效果。结果观察组治疗有效率高于对照组,起效时间、腹胀消失时间短于对照组,治疗后空腹血糖水平低于对照组,差异有统计学意义(P<0.05);治疗后两组各项便秘症状积分、血清血管活性肠肽(VIP)水平降低,且观察组更低,两组血清胃动素(MTL)、P物质(SP)水平升高,且观察组更高,差异有统计学意义(P<0.05)。结论首荟通便胶囊治疗2型糖尿病患者口服阿卡波糖后腹胀具有较好的临床疗效,可缩短药物起效时间以及腹胀消失时间,降低空腹血糖水平,调节胃肠激素水平,且无严重不良反应发生。 Objective To explore the efficacy and safety of Shouhui Tongbei capsule in the treatment of abdominal distension after oral acarbose in patients with type 2 diabetes.Methods Forty-eight patients with type 2 diabetes with abdominal distension after oral acarbose treated in Cangzhou Central Hospital from January to December 2021 were selected as the study objects,and were divided into control group and observation group according to random number table method,with 24 cases in each group.The control group was given life intervention,and the observation group was given Shouhui Tongqi capsule on the basis of the control group.The therapeutic effect of the two groups was compared.Results The effective rate of treatment in the observation group was higher than that in the control group,the onset time and disappearance time of abdominal distension were shorter than that in the control group,and the fasting blood glucose level after treatment was lower than that in the control group,the difference was statistically significant(P<0.05).After treatment,the scores of constipation symptoms and serum vasoactive intestinal peptide(VIP)levels in the two groups were decreased,and the observation group was lower,and the serum motilin(MTL)and serum Substance P(SP)levels in the two groups were increased,and the observation group was higher,the difference was statistically significant(P<0.05).Conclusion Shouhuitongbei capsule has a good clinical effect on abdominal distention in type 2 diabetes patients after oral acarbose,which can shorten the time of drug onset and disappearance of abdominal distention,reduce fasting blood glucose level,regulate gastrointestinal hormone level,and no serious adverse reactions.
作者 王晨曦 靳艳艳 郭亚楠 王丽晖 王佳 钱红霞 WANG Chen-Xi;JIN Yan-Yan;GUO Ya-Nan;WANG Li-Hui;WANG Jia;QIAN Hong-Xia(Department of Clinical Laboratory,Cangzhou Central Hospital,Cangzhou 061001,China;Department of Endocrinology,Cangzhou Central Hospital,Cangzhou 061001,China;Department of General Surgery,Anping County People's Hospital,Hengshui 053600,China)
出处 《中国药物经济学》 2024年第10期43-46,共4页 China Journal of Pharmaceutical Economics
关键词 首荟通便胶囊 2型糖尿病 阿卡波糖 腹胀 Shouhui Tongbei capsule Type 2 diabetes Acarbose Abdominal distension
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部